



06.10.2021

08:00 - 10:00 e-Posters

On-Demand

- 08:00 - 08:00 **6P - Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials**  
G. Alonso<sup>1</sup>, S. Aguilar<sup>1</sup>, F.J. Ros Montana<sup>1</sup>, H. Verdaguer<sup>1</sup>, A. Callejo Perez<sup>1</sup>, I. Brana<sup>1</sup>, I. Baraibar Argota<sup>1</sup>, P. Iranzo Gomez<sup>1</sup>, O. Saavedra Santa Gadea<sup>1</sup>, F. Salva Ballabrera<sup>1</sup>, D. Acosta Eyzaguirre<sup>1</sup>, M. Vieito Villar<sup>1</sup>, E. Garcia Torralba<sup>2</sup>, N.A. Wornham<sup>1</sup>, I. Faull<sup>3</sup>, J. Tabertero<sup>1</sup>, E. Felip<sup>1</sup>, E. Elez<sup>1</sup>, T. Macarulla Mercade<sup>1</sup>, E. Garraalda<sup>1</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>2</sup>Hospital Universitario Morales Meseguer, Murcia, ES, <sup>3</sup>Guardant Health Inc, Barcelona, ES
- 08:00 - 08:00 **7P - Predictive and prognostic value of cell-free DNA in plasma and pleural lavage among surgically treated adenocarcinomas of the lung (ADCL)**  
J. Saikia, P. Malik, S. Kumar, D. Jain, K. Madan, S. Bharati, S. Deo, S. Kumar, All India Institute of Medical Sciences, New Delhi, New Delhi, IN
- 08:00 - 08:00 **8P - Clinical trial design in the era of precision oncology: an overview of the last 20 years**  
M. Filetti<sup>1</sup>, P. Lombardi<sup>1</sup>, R. Falcone<sup>1</sup>, F. Paroni Sterbini<sup>1</sup>, G. Daniele<sup>2</sup>, <sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, <sup>2</sup>Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT
- 08:00 - 08:00 **9P - Late phase 1 studies: concepts and outcomes of a new clinical trial design**  
J.C. Benitez Montanez<sup>1</sup>, A. Geraud<sup>1</sup>, M. Texier<sup>1</sup>, C. Massard<sup>1</sup>, A. Paci<sup>1</sup>, J.-C. Soria<sup>1</sup>, B. Besse<sup>2</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, Cedex, FR, <sup>2</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 08:00 - 08:00 **10P - Clinical and morphological pattern of malignant tumors with microsatellite instability**  
A. Musaelyan<sup>1</sup>, S. Lapin<sup>2</sup>, V. Nazarov<sup>2</sup>, S. Vorobyev<sup>3</sup>, A. Zakharenko<sup>2</sup>, S. Orlov<sup>2</sup>, <sup>1</sup>Research Institute of Medical Primatology, Sochi, RU, <sup>2</sup>Pavlov First Saint Petersburg State Medical University, Saint Petersburg, RU, <sup>3</sup>National Center for Clinical Morphological Diagnostics, Saint Petersburg, RU
- 08:00 - 08:00 **11P - ROS1-gene rearranged lung adenocarcinomas: Demographic, clinicopathologic, and treatment profile in a cohort of indian patients**  
S. Mishra<sup>1</sup>, S. Mohanty<sup>2</sup>, <sup>1</sup>Apollo Cancer Center, Bhubaneswar, IN, <sup>2</sup>Advanced Medical Research Institute, Bhubaneswar, IN
- 08:00 - 08:00 **12P - Molecular features of KRAS mutant NSCLC: weaving a future score for immune-check point inhibitors (ICI).**  
M. Dorta Suarez, B. Jimenez Munarriz, A. Del Barrio, G. Garcia Ledo, R. Blanco Blanco, E. Conde Gallego, S. Hernandez Prieto, F. Lopez Rios, A. Cubillo Gracián, HM CIOCC - Centro Integral Oncológico Clara Campal, Madrid, ES



- 08:00 - 08:00 **13P - Incidental germline findings from tumor molecular profiling for precision oncology: is it common and how to manage?**  
M. Ivanov<sup>1</sup>, A. Lebedeva<sup>2</sup>, D. Seriak<sup>3</sup>, E. Rozhavskaia<sup>4</sup>, M. Sharova<sup>4</sup>, D. Vardhan<sup>5</sup>, A. Baranova<sup>5</sup>, J. Shaykhutdinova<sup>4</sup>, V. Mileyko<sup>4</sup>, <sup>1</sup>Moscow Institute of Physics and Technology, Dolgoprudny, RU, <sup>2</sup>Lomonosov Moscow State University, Moscow, RU, <sup>3</sup>First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, RU, <sup>4</sup>Atlas Oncodiagnostics, LLS, Moscow, RU, <sup>5</sup>George Mason university, Fairfax, US
- 08:00 - 08:00 **14P - Identification of age- associated genes as prognostic factors in non-small cell lung cancer**  
J. Liu<sup>1</sup>, A. Wang<sup>1</sup>, D. Trapani<sup>2</sup>, X. Sun<sup>3</sup>, X. Shan<sup>1</sup>, H. Al-Madani<sup>4</sup>, M.H.O. Safi<sup>5</sup>, <sup>1</sup>The first affiliated hospital of Dalian medical university, Dalian city, CN, <sup>2</sup>Istituto Europeo di Oncologia, Rome, IT, <sup>3</sup>Second affiliated hospital of Dalian medical university, Dalian city, CN, <sup>4</sup>University of Chinese Academy of Sciences, Beijing, CN, <sup>5</sup>Dalian Medical University, Dalian city, CN
- 08:00 - 08:00 **15P - FGFR3-TACC3 fusion (F) as an acquired resistance mechanism following treatment with EGFR TKIs and a suggested novel target in aNSCLC**  
R. Ari<sup>1</sup>, E. Dudnik<sup>2</sup>, D. Hershkovitz<sup>1</sup>, S. Jain<sup>3</sup>, L. Soussan-Gutman<sup>4</sup>, T. Ben Shitrit<sup>4</sup>, H. Nechushtan<sup>5</sup>, N. Peled<sup>6</sup>, A. Agbarya<sup>7</sup>, <sup>1</sup>Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, IL, <sup>2</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, <sup>3</sup>Guardant Health Pte. Ltd., Singapore, SG, <sup>4</sup>rhenium, Tel-Aviv, IL, <sup>5</sup>Hadassah University Hospital - Ein Kerem, Jerusalem, IL, <sup>6</sup>Shaare Zedek Medical Center, Jerusalem, IL, <sup>7</sup>Bnai Zion Medical Center, Haifa, IL
- 08:00 - 08:00 **16P - Evaluation of the Relationship between Clinicopathological Features at Diagnosis, and Acquisition of T790M Resistance Mutation in Patients with EGFR-mutant Metastatic Lung Cancer**  
I. Dogan, N. Khanmamadov, N. Paksoy, S. Vatansever, P. Saip, A. Aydiner, Istanbul University Institute of Oncology, Istanbul, TR
- 08:00 - 08:00 **17P - Genomic profiling of circulating tumour DNA in East Asian head and neck squamous cell carcinoma**  
N. Jia<sup>1</sup>, S. Zhang<sup>2</sup>, Y. Shi<sup>2</sup>, X. Shi<sup>1</sup>, C. Bai<sup>1</sup>, <sup>1</sup>PUMCH - Peking Union Medical College Hospital - Dongdan Campus, Beijing, CN, <sup>2</sup>Geneplus-Beijing, Beijing, CN
- 08:00 - 08:00 **18P - Precision radiotherapy for centrally located non-small cell lung cancer (NSCLC)**  
E.Y.W. Cheung, Y.C. Chan, K.Y. Cheng, Y.T. Cheng, H.Y. Yung, TWC-Tung Wah College:King's Park Campus, Kowloon, HK
- 08:00 - 08:00 **19P - Predictors of Osimertinib Response at Second-line Treatment in EGFR Mutant Non-small Cell Lung Cancer Patients with Acquired T790M Resistance Mutation**  
I. Dogan<sup>1</sup>, M. Gürbüz<sup>2</sup>, N. Paksoy<sup>1</sup>, N. Khanmamadov<sup>1</sup>, S. Vatansever<sup>1</sup>, P. Saip<sup>1</sup>, A. Demirkazik<sup>2</sup>, A. Aydiner<sup>1</sup>, <sup>1</sup>Istanbul University Institute of Oncology, Istanbul, TR, <sup>2</sup>Ankara University Faculty of Medicine, Ankara, TR



- 08:00 - 08:00 **20P - Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors**  
H. Taghizadeh<sup>1</sup>, R. Mader<sup>1</sup>, G. Prager<sup>1</sup>, L. Müllauer<sup>2</sup>, <sup>1</sup>Medical University of Vienna, Vienna, AT, <sup>2</sup>Medical University Vienna, Vienna, AT
- 08:00 - 08:00 **21P - COVID-19 cancer patients and thromboembolic disease: survival analysis**  
A. Pertejo, S. Martínez-Recio, D. Jiménez-Bou, J. Peña-López, I. Ruiz-Gutiérrez, G. Martín-Montalvo Pérez, A. Rueda-Lara, V. Martínez-Marín, Hospital Universitario La Paz, Madrid, ES
- 08:00 - 08:00 **22P - HGF and c-Met expression in metastatic endometrial cancer**  
O. Briieieva<sup>1</sup>, O. Movchan<sup>2</sup>, L. Buchynska<sup>1</sup>, <sup>1</sup>R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Science of Ukraine, Kiev, UA, <sup>2</sup>National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA
- 08:00 - 08:00 **23P - Transient multiple transfection of miR-181a into MCF-7 breast cancer cells induces irreversible resistance to tamoxifen**  
O. Andreeva<sup>1</sup>, V. Shatskaya<sup>1</sup>, D. Sorokin<sup>1</sup>, A. Scherbakov<sup>1</sup>, E. Mikhaevich<sup>1</sup>, M. Gudkova<sup>1</sup>, I. Bure<sup>2</sup>, E. Kuznetsova<sup>2</sup>, M. Nemtsova<sup>2</sup>, M. Krasil`Nikov<sup>1</sup>, <sup>1</sup>N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, Moscow, RU, <sup>2</sup>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, RU
- 08:00 - 08:00 **24P - TGF- $\beta$ RI contributes to tamoxifen response in luminal B breast cancer with HER2 negative phenotype**  
N. Babyshkina<sup>1</sup>, T. Dronova<sup>2</sup>, S. Vtorushin<sup>3</sup>, S. Patalyak<sup>3</sup>, N. Cherdyntseva<sup>3</sup>, <sup>1</sup>Tomsk National Research Medical Center, Tomsk, RU, <sup>2</sup>Tomsk National Research Medical Center, Russian Academy of Sciences, Cancer Research Institute, Tomsk, RU, <sup>3</sup>Tomsk National Research Medical Center of the Russian Academy of Sciences, Cancer Research Institute, Tomsk, RU
- 08:00 - 08:00 **25P - Early detection of breast cancer by liquid biopsy exploiting the DNA damage sensitivity (DDS)**  
R. Nussbaumer<sup>1</sup>, J. Godau<sup>2</sup>, R. Zanetti-Dällenbach<sup>3</sup>, A. Faisst<sup>2</sup>, O. Schicht<sup>2</sup>, Z. Barekati<sup>2</sup>, F. Staedtler<sup>2</sup>, B. Woelnerhanssen<sup>3</sup>, <sup>1</sup>University Hospital Basel, Basel, CH, <sup>2</sup>4D Lifetec AG, Cham, CH, <sup>3</sup>St. Claraspital, Basel, CH
- 08:00 - 08:00 **26P - The multi-switching activity of circulatory neutrophils in patients with Early Breast Cancer**  
A. Ramessur<sup>1</sup>, B. Ambasager<sup>1</sup>, I. Malanchi<sup>2</sup>, R.C. Coombes<sup>1</sup>, <sup>1</sup>Imperial College London, London, GB, <sup>2</sup>Francis Crick Institute, London, GB
- 08:00 - 08:00 **27P - Search for markers of breast carcinogenesis associated with ER status**  
T. Kalinina, V. Kononchuk, Federal Research Centre of Fundamental and Translational Medicine, Novosibirsk, RU



- 08:00 - 08:00 **28P - Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs)**  
N. Raut<sup>1</sup>, N. Kale<sup>2</sup>, A. D'Souza<sup>2</sup>, Y. Patil<sup>2</sup>, P. Chakraborty<sup>2</sup>, K. Prabhash<sup>3</sup>, P. Chaturvedi<sup>3</sup>, J. Khandare<sup>2</sup>, <sup>1</sup>Bhaktivedanta Hospital, thane, IN, <sup>2</sup>Actorius Innovations and Research, pune, IN, <sup>3</sup>Tata Memorial Hospital, mumbai, IN
- 08:00 - 08:00 **29P - Biological factors of breast cancer and DFS**  
D. Hussein, R. Mohamed, M.A. Mohamed, Assiut University Hospitals, Assiut, EG
- 08:00 - 08:00 **30P - Bioinformatics analysis for Lysyl Oxidases as therapeutic targets for breast cancer**  
S. Ramos, S. Ferreira, N. Saraiva, A. Fernandes, ULHT - Universidade Lusófona de Humanidades e Tecnologias, Lisbon, PT
- 08:00 - 08:00 **31P - Sulfhydryl groups in estrogen receptors**  
D. Burlaka, Institute for Problems of Cryobiology and Cryomedicine NAS, Kiev, UA
- 08:00 - 08:00 **32P - Immunoregulatory loop between let-7a and CCAT1 lncRNA coordinated by c-Myc underlies the PD-1/PD-L1 Immuno-resistance in Triple negative breast cancer patients**  
N. Selem, H. Nafae, R. Youness, M.Z. Gad, German University in Cairo, Cairo, EG
- 08:00 - 08:00 **33P - Prognostic values of different subtypes of KRAS mutations in pancreatic cancer**  
S. Smirnov, K. Hutkouskaya, K. Gremza, A. Portyanko, N.N. Alexandrov National Cancer Center of Belarus, Minsk, BY
- 08:00 - 08:00 **34P - Validation of A New Scoring System for Molecular Subtyping of Gastric Cancer**  
I. Cazacu<sup>1</sup>, A. Filippi<sup>2</sup>, V. Croitoru<sup>1</sup>, S. Kitahara<sup>3</sup>, A. Matsui<sup>3</sup>, G. Lauwers<sup>3</sup>, A. Sorop<sup>2</sup>, L. Necula<sup>4</sup>, L. Matei<sup>4</sup>, C. Pechianu<sup>2</sup>, A. Croitoru<sup>1</sup>, V. Herlea<sup>2</sup>, A. Saftoiu<sup>5</sup>, D. Paul<sup>6</sup>, M. Chivu-Economescu<sup>4</sup>, S. Dima<sup>2</sup>, D. Duda<sup>3</sup>, I. Popescu<sup>2</sup>, <sup>1</sup>Fundeni Clinical Institute, Bucharest, RO, <sup>2</sup>Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, RO, <sup>3</sup>Massachusetts General Hospital, Boston, US, <sup>4</sup>Stefan St. Nicolau Institute of Virology, Bucharest, RO, <sup>5</sup>University of Medicine and Pharmacy Craiova, Craiova, RO, <sup>6</sup>Weill Cornell Medicine, New York, US
- 08:00 - 08:00 **35P - Increased sensitivity to olaparib by BRCA1/2 knockdown using a CRISPR/Cas9-mediated knock-in method in pancreatic cancer cell lines.**  
A. Witz<sup>1</sup>, J. Dardare<sup>1</sup>, M. Husson<sup>2</sup>, A. Francois<sup>3</sup>, J.-L. Merlin<sup>3</sup>, P. Gilson<sup>1</sup>, A. Harlé<sup>1</sup>, <sup>1</sup>Université de Lorraine CNRS UMR 7039 CRAN, Service de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, FR, <sup>2</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-les-Nancy, FR, <sup>3</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR
- 08:00 - 08:00 **36P - Plasma levels of hsa\_circ\_0001445 and hsa\_circ\_0007915 may indicate the presence of metastatic disease in patients with colorectal cancer**



M. Radanova<sup>1</sup>, G. Mihaylova<sup>1</sup>, O. Tasinov<sup>1</sup>, D. Ivanova<sup>1</sup>, N. Nazifova-Tasinova<sup>1</sup>, R. Manev<sup>1</sup>, A. Salim<sup>1</sup>, M. Nikolova<sup>1</sup>, D. Ivanova<sup>1</sup>, N. Conev<sup>1</sup>, Z. Mihaylova<sup>2</sup>, I. Donev<sup>3</sup>,  
<sup>1</sup>Medical University of Varna, Varna, BG, <sup>2</sup>Military Medical Academy, Sofia Bulgaria, Sofia, BG, <sup>3</sup>Hospital Nadezhda, Sofia, Bulgaria, Sofia, BG

- 08:00 - 08:00 **37P - Prognostic Significance of Immune Checkpoint Molecule Expression in Resectable Gastric Adenocarcinoma**  
V. Croitoru<sup>1</sup>, A. Filippi<sup>2</sup>, I. Cazacu<sup>1</sup>, S. Kitahara<sup>3</sup>, A. Matsui<sup>3</sup>, G. Lauwers<sup>3</sup>, A. Sorop<sup>2</sup>, L. Necula<sup>4</sup>, L. Matei<sup>4</sup>, C. Pechianu<sup>2</sup>, A. Croitoru<sup>1</sup>, V. Herlea<sup>2</sup>, A. Saftoiu<sup>5</sup>, M. Chivu-Economescu<sup>4</sup>, S. Dima<sup>2</sup>, D. Duda<sup>3</sup>, I. Popescu<sup>2</sup>, <sup>1</sup>Fundeni Clinical Institute, Bucharest, RO, <sup>2</sup>Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, RO, <sup>3</sup>Massachusetts General Hospital, Boston, US, <sup>4</sup>Stefan St. Nicolau Institute of Virology, Bucharest, RO, <sup>5</sup>University of Medicine and Pharmacy Craiova, Craiova, RO
- 08:00 - 08:00 **38P - Prognostic Significance of Karyopherin Alpha 2 for Patients with Colorectal Cancer: A Review**  
J. Wijaya, A. Tan, UPH - Pelita Harapan University, Tangerang, ID
- 08:00 - 08:00 **39P - Prognostic value of Neutrophil-Lymphocyte ratio in patients with advanced pancreatic cancer**  
W. Ben Kridis, M. Lajnef, S. Khmiri, A. Khanfir, University of Sfax - Hopital Habib Bourguiba, sfax, TN
- 08:00 - 08:00 **40P - MALAT-1/miR-30a-5p ceRNA network Releases the Brakes of Immune Surveillance in Breast Cancer through its Quadruple Targets: PD-L1, MIF, IL-10 and TNF-?**  
A. Ramzy<sup>1</sup>, R. Youness<sup>1</sup>, T. Manie<sup>2</sup>, A. Sebak<sup>1</sup>, S. Mansour<sup>1</sup>, <sup>1</sup>German University in Cairo, Cairo, EG, <sup>2</sup>National Cancer Institute, Cairo, EG
- 08:00 - 08:00 **41P - Attenuation of p53 signaling by CDK8/19 sensitizes tumor cells to ionizing radiation**  
O. Kuchur<sup>1</sup>, A. Zavirskiy<sup>2</sup>, A. Shtil<sup>3</sup>, <sup>1</sup>ITMO University, Saint-Petersburg, RU, <sup>2</sup>Kirov Military Medical Academy, Saint Petersburg, RU, <sup>3</sup>Blokhin National Medical Research Center of Oncology, Moscow, RU
- 08:00 - 08:00 **42P - Method optimization for the detection of chimerism by real-time PCR and droplet digital PCR**  
I. Lambrescu, V. Ionescu, G. Gaina, A. Popa, C. Niculite, V. Cismasiu, Victor Babes Institute of Pathology, Bucuresti, RO
- 08:00 - 08:00 **43P - The effect of quercetin and doxorubicin treatment on the proliferative capacity of tumour cells**  
A. Diana<sup>1</sup>, A.M. Coman<sup>2</sup>, M. Crivineanu<sup>1</sup>, A. Busca<sup>2</sup>, M. Panait<sup>2</sup>, F. Iordache<sup>1</sup>, <sup>1</sup>University of Agriculture and Veterinary Medicine, Faculty of Veterinary Medicine, Bucharest, RO, <sup>2</sup>Institutul Oncologic Profesor Doctor Alexandru Trestioreanu, Bucharest, RO



- 08:00 - 08:00 **60P - CCL2 expression and the neutrophil plasma membrane characteristics in blood in different stages of endometrial cancer**  
T. Abakumova, S. Gening, T. Gening, Ulyanovsk State University, Ulyanovsk, RU
- 08:00 - 08:00 **46P - Enhanced ALA-based PDT Efficacy by hormones in uterine sarcoma cells via up-regulation of ferrochelatase**  
E. Chu<sup>1</sup>, H. Lau<sup>1</sup>, Z. Huang<sup>2</sup>, <sup>1</sup>TWC-Tung Wah College:King's Park Campus, Kowloon, HK, <sup>2</sup>Fujian Normal University, Fuzhou, CN
- 08:00 - 08:00 **47P - Comprehensive molecular analysis of tissue samples from cancer patients: Evaluation of a novel all-in-one NGS strategy for diagnosis and theranostic**  
J. Dardare<sup>1</sup>, A. Witz<sup>1</sup>, M. Husson<sup>2</sup>, J.-L. Merlin<sup>1</sup>, P. Gilson<sup>1</sup>, A. Harlé<sup>1</sup>, <sup>1</sup>Université de Lorraine CNRS UMR 7039 CRAN, Service de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, FR, <sup>2</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-les-Nancy, FR
- 08:00 - 08:00 **48P - Low glucose sensitizes A431 skin cancer cells to metformin treatments: A way forward to targeting PD-L1**  
A. Mikhailova<sup>1</sup>, A. Basharina<sup>1</sup>, D. Sorokin<sup>2</sup>, G. Buravchenko<sup>3</sup>, S. Samsonik<sup>1</sup>, T. Bogush<sup>1</sup>, A. Scherbakov<sup>2</sup>, <sup>1</sup>N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, RU, <sup>2</sup>N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, Moscow, RU, <sup>3</sup>Gause Institute of New Antibiotics, Moscow, RU
- 08:00 - 08:00 **49P - Identifying and validating networks of oncology biomarkers mined from the scientific literature**  
K. Wager<sup>1</sup>, D. Chari<sup>2</sup>, S. Ho<sup>2</sup>, T. Rees<sup>1</sup>, O. Penner<sup>3</sup>, B. Schijvenaars<sup>3</sup>, <sup>1</sup>Oxford PharmaGenesis Ltd, Oxford, GB, <sup>2</sup>Pfizer Inc., New York, US, <sup>3</sup>Digital Science, London, GB
- 08:00 - 08:00 **50P - Transcriptomic Analysis of Host Immune Response for Precision Drug Prediction for SARS-CoV-2 Infected Patients- An Evidence-Based Approach**  
A. Bohra, All India Institute of Medical Sciences Bhopal, Bhopal, IN
- 08:00 - 08:00 **62P - Pyrrole-based carboxamides exhibit potent cytotoxic activities against epithelial cancer cell lines via targeting tubulin polymerization**  
S. Boichuk<sup>1</sup>, A. Galembikova<sup>1</sup>, F. Bikinieva<sup>2</sup>, P. Dunaev<sup>2</sup>, S. Zykova<sup>3</sup>, N. Igidov<sup>3</sup>, <sup>1</sup>KSMU - Kazan State Medical University, Kazan, RU, <sup>2</sup>KSMU - Kazan State Medical University, ??????, RU, <sup>3</sup>Perm State Academy of Pharmacy, Perm, RU
- 08:00 - 08:00 **51P - A Novel Crosstalk between Pyridoxal 5'-Phosphate (PLP)-Dependent Enzymes; CBS & CSE Modulated by MALAT-1/STAT-3 Axis**  
N. Khater<sup>1</sup>, R.A. Youness<sup>2</sup>, D. Habashy<sup>2</sup>, M.Z. Gad<sup>3</sup>, <sup>1</sup>GUC - German University in Cairo, Giza, EG, <sup>2</sup>GUC - German University in Cairo, Cairo, EG, <sup>3</sup>German University in Cairo, Cairo, EG
- 08:00 - 08:00 **52P - MiRNA profile associated with the invasiveness in non-functioning pituitary adenomas**



E. Nikolova<sup>1</sup>, B. Georgieva<sup>1</sup>, S. Klenderova<sup>1</sup>, A. Elenkova<sup>1</sup>, A. Hadzhiyanev<sup>2</sup>, A. Todorova<sup>1</sup>, <sup>1</sup>Medical University Sofia, Sofia, BG, <sup>2</sup>University Hospital "St. Ivan Rilski", Medical University Sofia, Sofia, BG

- 08:00 - 08:00 **53P - Expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy**  
A. Nurgalieva<sup>1</sup>, S. Safina<sup>2</sup>, E. Shakirova<sup>2</sup>, V. Filonenko<sup>3</sup>, V. Skripova<sup>1</sup>, L. Bulatova<sup>1</sup>, D. Savenkova<sup>1</sup>, M. Bogdanov<sup>4</sup>, R. Kiyamova<sup>1</sup>, <sup>1</sup>Kazan Federal University, Kazan, RU, <sup>2</sup>Republican Clinical Oncological Dispensary, Kazan, RU, <sup>3</sup>Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv, UA, <sup>4</sup>University of Texas Health Science Center, Houston, US
- 08:00 - 08:00 **54P - Identification of patient-specific T cell neoantigens through HLA-agnostic genetic screens**  
W. Scheper<sup>1</sup>, C. Cattaneo<sup>1</sup>, J. Urbanus<sup>1</sup>, T. Battaglia<sup>1</sup>, J. Haanen<sup>2</sup>, E. Voest<sup>3</sup>, T. Schumacher<sup>1</sup>, <sup>1</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, <sup>3</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 08:00 - 08:00 **55P - Clinical Landscape of LAG-3-Targeted Therapy**  
L. Chocarro<sup>1</sup>, E. Blanco<sup>1</sup>, H. Arasanz<sup>2</sup>, A. Bocanegra<sup>1</sup>, L. Fernández-Rubio<sup>1</sup>, M. Echaide<sup>1</sup>, M. Garnica<sup>1</sup>, P. Ramos<sup>1</sup>, G. Fernández-Hinojal<sup>2</sup>, R. Vera<sup>2</sup>, G. Kochan<sup>1</sup>, D. Escors<sup>1</sup>, <sup>1</sup>Navarrabiomed-Public University of Navarre, IdISNA, Pamplona, ES, <sup>2</sup>Complejo Hospitalario de Navarra CHN-IdISNA, Pamplona, ES
- 08:00 - 08:00 **56P - Continuation treatment with immunotherapy beyond two years in patients with metastatic non-small cell lung cancer: retrospective analysis of optimal duration treatment.**  
P.B. Andres Vicente, J. Garde Noguera, J. García Sanchez, N. Piera, T. Fenollosa Sanz, P. Llor Rodriguez, J. Iranzo Barreira, P. Riquelme Cabrera, M.L. Fernandez Murga Chavanne, A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES
- 08:00 - 08:00 **61P - Characterization of EMC2 gene as a potential prognostic marker of tumor diseases**  
R. Valsenkova, J. Sultanova, V. Skripova, R. Kiyamova, Kazan Federal University, Kazan, RU
- 08:00 - 08:00 **58P - Clinically Actionable Outcomes of Next-generation Gene Sequencing Test in Advanced Solid Tumours in an Eastern Caribbean Nation**  
N. Shanbhag, S. Goodwin, Sir Lester Bird Mount St John's Medical Centre, St John's, AG
- 08:00 - 08:00 **59P - Berberine Chloride inhibits TNBC cell metastasis by downregulating expression of matrix metalloproteinases**  
S. Rajoriya<sup>1</sup>, M. Kataria<sup>2</sup>, N. Kumar<sup>3</sup>, M. Saini<sup>2</sup>, A. Kumar<sup>2</sup>, <sup>1</sup>Nanaji Deshmukh Veterinary Science University, Jabalpur, IN, <sup>2</sup>Indian Veterinary Research Institute, Bareilly, IN, <sup>3</sup>Tamilnadu Animal Husbandary Department Veterinary Research Institute, Tamilnadu, IN




- 08:00 - 08:00 **63P - Inhibition of AKT-signalling sensitizes A673 Ewing sarcoma cell line to doxorubicin**  
A. Galembikova, S. Boichuk, KSMU - Kazan State Medical University, Kazan, RU
- 08:00 - 08:00 **64P - Tyrosine kinase signaling profile in osteosarcomas - a potential therapeutic target for sensitization to doxorubicin**  
A. Galembikova, S. Boichuk, KSMU - Kazan State Medical University, Kazan, RU
- 08:00 - 08:00 **65P - Oxidative stress associated with Cu<sup>2+</sup> to Cu<sup>+</sup> reduction for eradicating wild type and multidrug resistant tumor cells**  
S. Tsymbal<sup>1</sup>, N. Agadzhanian<sup>1</sup>, A. Shtil<sup>2</sup>, <sup>1</sup>ITMO, Saint-Petersburg, RU, <sup>2</sup>Blokhin National Medical Research Center of Oncology, Moscow, RU
- 08:00 - 08:00 **66P - TGF- $\beta$ 1, a crucial mediator of radioiodine therapy-induced anti-tumor immunity**  
A. Stanciu<sup>1</sup>, M. Bolovan<sup>1</sup>, A. Zamfirescu<sup>1</sup>, M. Stanciu<sup>2</sup>, M. Panait<sup>1</sup>, <sup>1</sup>Institutul Oncologic Profesor Doctor Alexandru Trestioreanu, Bucharest, RO, <sup>2</sup>University Politehnica of Bucharest, Bucharest, RO
- 08:00 - 08:00 **67P - Challenges to Molecular testing for selecting targeted therapies for Oncology Patients in India**  
V.P.B. Koyyala<sup>1</sup>, P. Kulkarni<sup>2</sup>, V. Goel<sup>3</sup>, S.C. Goteti<sup>4</sup>, S. Raj Purohit<sup>5</sup>, A. Jajodia<sup>3</sup>, S.R. Ch<sup>6</sup>, P. Medisetty<sup>7</sup>, P. Goyal<sup>3</sup>, M. La Mantia<sup>8</sup>, C. Dodagoudar<sup>9</sup>, S. Pasricha<sup>3</sup>, S. Sen<sup>10</sup>, <sup>1</sup>Assam Cancer Care Foundation, Tezpur, IN, <sup>2</sup>Deenanath Mangeshkar hospital and research center, pune, IN, <sup>3</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>4</sup>Indraprastha Apollo hospitals, New Delhi, IN, <sup>5</sup>BLK and MAX super specialty hospital, New Delhi, IN, <sup>6</sup>Omega Hospitals, hyderabad, IN, <sup>7</sup>BSAH - Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, IN, <sup>8</sup>AOU Policlinico "Paolo Giaccone", Palermo, IT, <sup>9</sup>BLK Superspeciality Hospital, New Delhi, IN, <sup>10</sup>Assam Cancer Care Foundation, Guwahati, IN
- 08:00 - 08:00 **71P - Breast cancer cells taxol-resistance is associated with cytoplasmic actin isoforms balance shift and acquisition of more malignant phenotype.**  
M. Novikova<sup>1</sup>, V. Dugina<sup>2</sup>, S. Boichuk<sup>3</sup>, B. Kopnin<sup>1</sup>, P. Kopnin<sup>1</sup>, <sup>1</sup>N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, <sup>2</sup>Lomonosov Moscow State University, Moscow, RU, <sup>3</sup>KSMU - Kazan State Medical University, Kazan, RU
- 08:00 - 08:00 **72P - Targeting androgen receptor splice variant 7 in 22Rv1 prostate cancer cells**  
A. Scherbakov<sup>1</sup>, M. Barysevich<sup>2</sup>, M. Laktsevich-Iskryk<sup>2</sup>, O. Andreeva<sup>1</sup>, D. Sorokin<sup>1</sup>, D. Salnikova<sup>3</sup>, A. Hurski<sup>2</sup>, V. Zhabinskii<sup>2</sup>, V. Khripach<sup>2</sup>, <sup>1</sup>N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, Moscow, RU, <sup>2</sup>Institute of Bioorganic Chemistry, Minsk, RU, <sup>3</sup>Blokhin N.N. National Medical Research Center of Oncology, Moscow, RU
- 08:00 - 08:00 **73P - Studying the immune microenvironment favouring initiation of invasion in cervical carcinoma**




O. Kurmyshkina, T. Volkova, Petrozavodsk State University (PetrSU), Petrozavodsk, RU

- 08:00 - 08:00 **68P - Nuclear structures upon changes in the expression of cytoplasmic actin isoforms**  
V. Dugina<sup>1</sup>, S. Panina<sup>2</sup>, M. Novikova<sup>3</sup>, P. Kopnin<sup>3</sup>, <sup>1</sup>Lomonosov Moscow State University, Moscow, RU, <sup>2</sup>Moscow State University, Moscow, RU, <sup>3</sup>N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 08:00 - 08:00 **69P - HER2 status in RAS and BRAF wild-type metastatic colorectal cancer - Portuguese study**  
M.J. De Sousa, T. Fraga, J. Correia Magalhães, R. Basto, J. Paulo, P. Jacinto, N. Bonito, J.P. Magalhães, P. Figueiredo, G. Sousa, Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT
- 08:00 - 08:00 **70P - Local features of germinal mutations incidence in cancer patients in Republic of Bashkortostan**  
A. Sultanbaev, K. Menshikov, A. Nasretdinov, S. Musin, R. Rakhimov, N. Sultanbaeva, O. Lipatov, Republican Clinical Oncology Dispensary - Ufa, Ufa, RU
- 08:00 - 08:00 **74P - Exosome profiling reveals prognostic markers of response to Cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)**  
I. Vardaki<sup>1</sup>, S. Sabah Ozcan<sup>2</sup>, P. Fonseca<sup>1</sup>, A. Ullen<sup>3</sup>, J. Yachnin<sup>3</sup>, T. Panaretakis<sup>4</sup>, <sup>1</sup>Karolinska Institutet, Solna, SE, <sup>2</sup>School of Medicine Manisa Celal Bayar University, Manisa, TR, <sup>3</sup>Karolinska University Hospital, Stockholm, SE, <sup>4</sup>MD Anderson Cancer Center, TEXAS, US
- 08:00 - 08:00 **75P - Karyopherin Alpha 2 Role in Determining Outcome for Patients with Bladder Cancer: A Systematic Review and Meta-Analysis**  
A. Tan, J. Wijaya, UPH - Pelita Harapan University, Tangerang, ID
- 08:00 - 08:00 **76P - B7-H3 immune checkpoint protein expression is associated with immune exhaustion, overall survival and metastasis in clear cell renal cell carcinoma**  
C. Nunes-Xavier<sup>1</sup>, M. Emaldi<sup>2</sup>, T. Øyjord<sup>3</sup>, G. Larrinaga<sup>2</sup>, P. Errarte<sup>2</sup>, J. Angulo<sup>4</sup>, R. Llarena<sup>5</sup>, G. Mælandsmo<sup>3</sup>, Ø. Fodstad<sup>3</sup>, R. Pulido<sup>2</sup>, J. López<sup>2</sup>, <sup>1</sup>Asociación Instituto de Investigación Sanitaria BioCruces, Barakaldo, ES, <sup>2</sup>Instituto de Investigación Sanitaria BioCruces, Barakaldo, ES, <sup>3</sup>Oslo University Hospital, Institute for Cancer Research, Oslo, NO, <sup>4</sup>University Hospital of Getafe, Madrid, ES, <sup>5</sup>Cruces University Hospital, Barakaldo, ES
- 08:00 - 08:00 **44P - Value of comprehensive genomic profiling in pre-screening patients for NTRK fusion in STARTRK2 trial - single centre experience**  
A. Ortega Franco<sup>1</sup>, A. Adamson-Raieste<sup>1</sup>, R. Rahman<sup>1</sup>, R. Pihlak<sup>1</sup>, N. Peters<sup>1</sup>, J.-A. Scott<sup>1</sup>, S. Aruketty<sup>1</sup>, C. Thomson<sup>1</sup>, S. Dransfield<sup>1</sup>, A. Henshaw<sup>1</sup>, A. Ward<sup>1</sup>, T. Cutts<sup>1</sup>, L. Carter<sup>1</sup>, F. Thistlethwaite<sup>1</sup>, N. Cook<sup>1</sup>, D.M. Graham<sup>1</sup>, J. Stevenson<sup>2</sup>, M. Krebs<sup>1</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, GB



- 08:00 - 08:00 **45P - Environmental Scan of Molecular Profiling in Canada**  
M. El Bizri, Colorectal Cancer Canada, Montreal, CA
- 08:00 - 08:00 **57P - Patients' and Caregivers' Perspective on Biomarker Testing Across Canada**  
M. El Bizri, L. Sukkarieh, B. Stein, Colorectal Cancer Canada, Montreal, CA
- 08:00 - 08:00 **77P - B7-H4 immune checkpoint protein as mediator of resistance to targeted therapy in renal cancer cells**  
M. Emaldi<sup>1</sup>, C. Nunes-Xavier<sup>2</sup>, <sup>1</sup>IIS Biocruces Bizkaia, Barakaldo, ES, <sup>2</sup>Asociación Instituto de Investigación Sanitaria BioCruces, Barakaldo, ES
- 08:00 - 08:00 **78P - Coexpression of CD44 and CD133 as cancer stem cells (CSC) markers in prostate cancer (PCa) tissue**  
M. Puchinskaya, Minsk City Clinical Cancer Center, Minsk, BY
- 08:00 - 08:00 **79P - The potential benefits of urinary and blood liquid biopsies for predicting early diagnosis, therapy response, and prognosis in renal cell carcinoma patients: A systematic review**  
B.P. Putra<sup>1</sup>, F.N. Putra<sup>2</sup>, <sup>1</sup>Medical Doctor, Blitar, ID, <sup>2</sup>Faculty of Medicine Universitas Airlangga, Surabaya, ID
- 08:00 - 08:00 **80P - HER2 expression in primary bladder tumors and paired regional lymph nodes: relationship to cell cycle profile**  
M. Dumitru<sup>1</sup>, M. Mihaila<sup>2</sup>, C. Hotnog<sup>2</sup>, M. Panait<sup>3</sup>, M. Vasilescu<sup>3</sup>, M. Hortopan<sup>4</sup>, L. Brasoveanu<sup>2</sup>, <sup>1</sup>Institute of Oncology "Prof.Dr. Al. Trestioreanu, Bucharest, RO, <sup>2</sup>Stefan S. Nicolau Institute of Virology, Bucharest, RO, <sup>3</sup>Institute of Oncology "Prof.Dr. Al. Trestioreanu", Bucharest, RO, <sup>4</sup>Clinical Institute Fundeni, Bucharest, RO
- 08:00 - 08:00 **81P - Safety and effectiveness of apalutamide for the treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nm-CRPC): preliminary results from an Open-Label Expanded Access Protocol (EAP)**  
S. Campos-Gomez<sup>1</sup>, J. Ochoa<sup>2</sup>, F. Cruz<sup>3</sup>, A. Mota<sup>4</sup>, M. Rios<sup>5</sup>, J. Rinck Jr<sup>6</sup>, A. Bhaumik<sup>7</sup>, M. Grings<sup>8</sup>, A. Acerbi<sup>8</sup>, K. Salomão<sup>8</sup>, V. Fabricio<sup>9</sup>, R. Gidekel<sup>10</sup>, <sup>1</sup>Centro Oncológico Estatal ISSEMYM, Toluca, MX, <sup>2</sup>HOSPITAL PABLO TOBÓN URIBE, Medellin, CO, <sup>3</sup>IBCC - INSTITUTO BRASILEIRO DE CONTROLE DO CANCER, São Paulo, BR, <sup>4</sup>Clínica AMO, Salvador, BR, <sup>5</sup>INCAN -Instituto Nacional de Cancerologia Mexico, Ciudad de México, MX, <sup>6</sup>A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR, <sup>7</sup>Janssen Pharmaceuticals, New Jersey, US, <sup>8</sup>Janssen-Cilag Ltda., São Paulo, BR, <sup>9</sup>Janssen-Cilag Farmaceutica Ltda., Sao Paulo, BR, <sup>10</sup>Janssen Cilag Farmacéutica S.A, Buenos Aires, AR
- 08:00 - 08:00 **82P - Correlations of androgen receptor (AR) and transforming growth factor beta receptor type 2 (TGFbR2) expression in prostate cancer (PCa)**  
M. Puchinskaya, Minsk City Clinical Cancer Center, Minsk, BY
- 08:00 - 08:00 **83TiP - Clinical Implications of Clonal Hematopoiesis Mutations in Patients with Solid Tumors**




V. Croitoru<sup>1</sup>, I. Cazacu<sup>1</sup>, D. Paul<sup>2</sup>, A. Colita<sup>1</sup>, C. Lungulescu<sup>3</sup>, V. Herlea<sup>4</sup>, N.I. Luca<sup>1</sup>, D. Bogdan<sup>1</sup>, I. Sandra<sup>1</sup>, I.-M. Gramaticu<sup>1</sup>, F. Buica<sup>1</sup>, M. Dinu<sup>1</sup>, A. Sorop<sup>4</sup>, S. Dima<sup>4</sup>, I. Popescu<sup>4</sup>, A. Croitoru<sup>1</sup>, T. Alina<sup>1</sup>, <sup>1</sup>Fundeni Clinical Institute, Bucharest, RO, <sup>2</sup>Weill Cornell Medicine, New York, US, <sup>3</sup>Oncolab Craiova, Craiova, RO, <sup>4</sup>Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, RO

08:00 - 08:00

**84TiP - Predictive Value of Exosomes for Therapy Response in Resectable/Borderline Resectable Pancreatic Cancer Patients**

I. Cazacu<sup>1</sup>, D. Paul<sup>2</sup>, E. Popa<sup>2</sup>, I. Matei<sup>2</sup>, C. Gheorghe<sup>1</sup>, V. Herlea<sup>3</sup>, M. Diculescu<sup>1</sup>, D. Bogdan<sup>1</sup>, I. Sandra<sup>1</sup>, I.-M. Gramaticu<sup>1</sup>, N.I. Luca<sup>1</sup>, I. Dinu<sup>1</sup>, S. Alexandrescu<sup>1</sup>, A. Sorop<sup>3</sup>, A. Croitoru<sup>1</sup>, S. Dima<sup>3</sup>, I. Popescu<sup>3</sup>, D. Lyden<sup>2</sup>, <sup>1</sup>Fundeni Clinical Institute, Bucharest, RO, <sup>2</sup>Weill Cornell Medicine, New York, US, <sup>3</sup>Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, RO



07.10.2021

**14:15 - 15:30 Workshop: Update on new technologies (part 1) Channel 1**  
Moderation: D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:15 - 14:35 **Basics in bioinformatics**  
N. Mcgranahan, UCL Cancer Institute - Paul O'Gorman Building, London, GB

14:35 - 14:55 **AI for dummies**  
N. Paragios, CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR

14:55 - 15:15 **Circulating markers**  
B. O'Leary, The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB

15:15 - 15:30 **Live Q&A**


**15:45 - 16:45 Workshop: Update on new technologies (part 2) Channel 1**  
Moderation: D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:45 - 16:05 **Profiling intratumoral immune responses**  
D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:05 - 16:25 **Technologies to assess epigenetics**  
T. Sourisseau, Institut Gustave Roussy, Villejuif, FR

16:25 - 16:45 **Live Q&A**

**17:00 - 18:00 Novartis - Addressing the increasing complexity of biomarker detection in NSCLC: A real-world multidisciplinary perspective Channel 1**



08.10.2021

**12:10 - 12:15 Welcome to the MAP Virtual Congress 2021 Channel 1**

Moderation: F. André<sup>1</sup>, C. Swanton<sup>2</sup>, J. Haanen<sup>3</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Francis Crick Institute, London, GB, <sup>3</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

**12:15 - 13:30 Molecular characterisation Channel 1**

Moderation: P. Campbell, Wellcome Trust Sanger Institute, Cambridge, GB

12:15 - 12:30 **Genomic landscape of normal tissue**

P. Campbell, Wellcome Trust Sanger Institute, Cambridge, GB

12:30 - 12:45 **Endometrial cancers**

T. Bosse, Leiden University Medical Center, Leiden, NL


12:45 - 13:00 **Basal cell carcinoma**

S. Nikolaev, Institut Gustave Roussy, Villejuif, Cedex, FR


13:00 - 13:15 **Genomic characterization of metastatic cancers**

J. Van De Haar, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

13:15 - 13:30 **Live Q&A**



<b>12:15 - 13:30</b>	<b>Clonal evolution</b>	<b>Channel 2</b>
	Moderation: S. Turajlic, The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
12:15 - 12:30	<b>Genomic evolution in brain metastases: Implications for precision medicine</b>	
	<u>P. Brastianos</u> , Massachusetts General Hospital, Boston, US	
12:30 - 12:45	<b>Mathematical model perspective: Genotype-phenotype map</b>	
	<u>A. Anderson</u> , H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US	
12:45 - 13:00	<b>Inactivation of DNA repair and high dose vitamin C boost cancer immunotherapy</b>	
	<u>A. Bardelli</u> , IRCCS - Istituto di Candiolo - FPO, Candiolo, IT	
13:00 - 13:15	<b>Clonal evolution through representative sequencing</b>	
	<u>S. Turajlic</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
13:15 - 13:30	<b>Live Q&amp;A</b>	
<b>13:45 - 14:15</b>	<b>Keynote lecture</b>	<b>Channel 1</b>
	Moderation: J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
13:45 - 13:50	<b>Introduction</b>	
	<u>J. Haanen</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
13:50 - 14:15	<b>Understanding immune reactivation by immune checkpoint blockade in human cancer using ex vivo avatars</b>	
	<u>T. Schumacher</u> , The Netherlands Cancer Institute, Amsterdam, NL	



**14:30 - 15:45 Tumour crosstalk with the microenvironment in metastasis** **Channel 2**  
Moderation: G. Evan, University of Cambridge, Cambridge, GB

14:30 - 14:45 **How and why Myc controls the crosstalk between cancer cells and immune cells**  
G. Evan, University of Cambridge, Cambridge, GB

14:45 - 15:00 **How cancer cell-macrophage crosstalk promotes leptomeningeal metastasis**  
A. Boire, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:00 - 15:15 **Using single cell genomics to dissect how cancer chromosomal instability shapes a pro-metastatic tumour microenvironment**  
A. Laughney, Weill Cornell Medicine, New York, US

15:15 - 15:30 **The role of commensal interactions during metastasis**  
I. Malanchi, Francis Crick Institute, London, GB

15:30 - 15:45 **Live Q&A**

**14:30 - 15:45 Metastases (cancer cell intrinsic)** **Channel 1**  
Moderation: C. Curtis, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford, US


14:30 - 14:45 **Chromosomal instability through metastatic progression**  
N. Mcgranahan, UCL Cancer Institute - Paul O'Gorman Building, London, GB

14:45 - 15:00 **Imaging the metastatic cascade**  
J. Van Rheenen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

15:00 - 15:15 **Recapitulating metastatic regeneration in human organoids**  
K. Ganesh, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:15 - 15:30 **Genome architecture and determinants of therapy response in metastatic breast cancer**  
C. Curtis, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford, US

15:30 - 15:45 **Live Q&A**



<b>16:00 - 17:00</b>	<b>Mini Oral session</b>	<b>Channel 1</b>
Moderation: J. Downward <sup>1</sup> , C. Le Tourneau <sup>2</sup> , <sup>1</sup> London, GB, <sup>2</sup> Paris, FR		
16:00 - 16:07	<b>1MO - Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation</b>	
	<u>T. Sen</u> , New-York, US	
16:07 - 16:14	<b>2MO - XPO1 inhibition strongly sensitizes to first and second line therapy in small cell lung cancer</b>	
	<u>Á. Quintanal-Villalonga</u> , New-York, US	
16:14 - 16:21	<b>3MO - Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE. A reservoir for intrinsic resistance to KRAS G12C inhibitors?</b>	
	<u>D. Marinelli</u> , Ospedale Sant'Andrea, Rome, IT	
16:21 - 16:31	<b>Invited discussant: 1MO, 2MO, 3MO</b>	
	<u>J. Downward</u> , London, GB	
16:31 - 16:38	<b>4MO - p53 and p16ink4a As Predictive and Prognostic Biomarkers for Nodal metastasis and Survival in A Contemporary Cohort of Penile Squamous Cell Carcinoma.</b>	
	<u>S. Mishra</u> , Apollo Cancer Center, Bhubaneswar, IN	
16:38 - 16:45	<b>5MO - Prognostic intra-tumoural heterogeneity in cancer-associated fibroblasts (CAFs) is linked to evolution of tumour from normal in pancreatic cancer</b>	
	<u>A. Hussain</u> , ICR - Institute of Cancer Research, London, GB	
16:45 - 16:55	<b>Invited discussant: 4MO, 5MO</b>	
	<u>C. Le Tourneau</u> , Paris, FR	
16:55 - 17:00	<b>Live Q&amp;#38;A</b>	
	<u>A. Speakers</u> , , CH	
<b>17:15 - 18:15</b>	<b>Vesalius talk: How to stay informed using ESMO online resources</b>	<b>Channel 1</b>
Moderation: T. Amaral <sup>1</sup> , A. Passaro <sup>2</sup> , <sup>1</sup> , DE, <sup>2</sup> Milan, IT		



09.10.2021

**11:00 - 12:00 Amgen - Targeting KRAS: Past, present and future** **Channel 1**  
Moderation: C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB

11:00 - 11:05 **Welcome and Introduction**

C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB

11:05 - 11:20 **Structural basis of direct RAS inhibition**

K. Westover, Ken Westover Lab, Dallas, US

11:20 - 11:35 **RAS G12C inhibitors: Clinical considerations**

C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB

11:35 - 11:50 **Targeting KRAS: Pre-clinical validation and therapeutic perspectives to overcome drug resistance**

C. Ambrogio, Università degli Studi di Torino - Centro Interdipartimentale di Ricerca, Turin, IT

11:50 - 12:00 **Live Q&A and discussion**

C. Lindsay<sup>1</sup>, K. Westover<sup>2</sup>, C. Ambrogio<sup>3</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Ken Westover Lab, Dallas, US, <sup>3</sup>Università degli Studi di Torino - Centro Interdipartimentale di Ricerca, Turin, IT

**12:15 - 13:30 Lung cancer** **Channel 1**  
Moderation: C. Abbosh, St. James's University Hospital Leeds, Leeds, GB

12:15 - 12:30 **Detection of early-stage lung cancer using ctDNA**

M. Diehn, Stanford Comprehensive Cancer Institute, Stanford, US

12:30 - 12:45 **Tracking subclonal dynamics in relapsing NSCLC**

A. Frankell, Francis Crick Institute, London, GB


12:45 - 13:00 **The landscape of pre-invasive lung cancer lesions**

S. Janes, UCLH - University College London Hospitals NHS Foundation Trust, London, GB

13:00 - 13:15 **Immune alterations associated with progression of bronchial pre-malignant lesions**

A. Spira, BUSM - Boston University School of Medicine, Weston, US

13:15 - 13:30 **Live Q&A**



<b>12:15 - 13:30</b>	<b>Early detection</b>	<b>Channel 2</b>
	Moderation: S. Delaloge, Institut Gustave Roussy, Villejuif, FR	
12:15 - 12:30	<b>Germline genetic testing for cancer early detection: Is the time ripe?</b> <u>D. Evans</u> , The University of Manchester, Manchester, GB	
12:30 - 12:45	<b>Can somatic variants distinguish benign from aggressive premalignant lesions?</b> <u>D. Wedge</u> , The University of Manchester, Manchester, GB	
12:45 - 13:00	<b>Can blood biomarkers detect cancer early?</b> <u>S.-J. Dawson</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
13:00 - 13:15	<b>How will the integration of AI improve image-based early detection of cancers?</b> <u>F. Gilbert</u> , University of Cambridge, Cambridge, GB	
13:15 - 13:30	<b>Live Q&amp;A</b>	
<b>13:45 - 14:15</b>	<b>Gordon Peters lecture</b>	<b>Channel 1</b>
	Moderation: C. Swanton, Francis Crick Institute, London, GB	
13:45 - 13:50	<b>Introduction</b> <u>C. Swanton</u> , Francis Crick Institute, London, GB	
13:50 - 14:15	<b>Exploring and therapeutically exploiting the tumour microenvironment</b> <u>J. Joyce</u> , Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Lausanne, CH	



**14:30 - 15:45**    **Transcription and translation inhibitors in cancer treatment**    **Channel 2**  
Moderation: A. Aguilera, Universidad de Sevilla, Seville, ES

14:30 - 14:45    **Lurbinectedin and other transcription inhibitors in lung cancer**  
L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

14:45 - 15:00    **HDAC inhibitor romidepsin in cancer**  
S. Bates, Columbia University, New York, US

15:00 - 15:15    **RNA processing and tumorigenesis and his genomic approaches**  
G. Tonon, IRCCS Ospedale San Raffaele, Milan, IT

15:15 - 15:30    **Targeting mRNA translation initiation in melanoma**  
S. Vagner, Institut Gustave Roussy, Villejuif, FR

15:30 - 15:45    **Live Q&A**

**14:30 - 15:45**    **Spatial techniques for the tumour microenvironment**    **Channel 1**  
Moderation: F. André, Gustave Roussy - Cancer Campus, Villejuif, FR


14:30 - 14:45    **Next-generation Slide-seq for high-resolution gene expression profiling**  
F. Chen, Harvard University, Cambridge, US

14:45 - 15:00    **Spatial transcriptomics for mapping the spatial architecture of cancers**  
J. Lundeberg, Science for Life Laboratory (SciLifeLab), Solna, SE

15:00 - 15:15    **High spatial-resolution multi-omics via DBiT-seq**  
R. Fan, Yale University School of Medicine - Yale Cancer Center, New Haven, US

15:15 - 15:30    **Multimodal interrogation of the tumour microenvironment**  
Y. Yuan, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

15:30 - 15:45    **Live Q&A**



<b>16:00 - 17:15</b>	<b>Myeloid targets for immunotherapy</b> Moderation: M. Kok, Netherlands Cancer Institute, Amsterdam, NL	<b>Channel 1</b>
16:00 - 16:15	<b>Tumour-associated macrophage heterogeneity</b> <u>F. Ginhoux</u> , A*STAR - Singapore Immunology Network (SIgN), Singapore, SG	
16:15 - 16:30	<b>Critical role for eosinophils during response to immune checkpoint blockade</b> <u>M. Kok</u> , Netherlands Cancer Institute, Amsterdam, NL	
16:30 - 16:45	<b>DC functionality &amp; anti-cancer immune responses</b> <u>M. Merad</u> , Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US	
16:45 - 17:00	<b>PD-L1 on tumor-infiltrating myeloid cells</b> <u>I. Mellman</u> , Genentech, Inc., South San Francisco, US	
17:00 - 17:15	<b>Live Q&amp;A</b>	
<b>17:15 - 17:20</b>	<b>Closing remarks</b> Moderation: F. André <sup>1</sup> , J. Haanen <sup>2</sup> , C. Swanton <sup>3</sup> , <sup>1</sup> Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup> Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, <sup>3</sup> Francis Crick Institute, London, GB	<b>Channel 1</b>